ReviewCancer cell international2024
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.
Review in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment.Nanoscale advances · 2026Article
- A multi-scale adaptive filtering and AtRes_SRU-transformer synergy for breast cancer histopathology classification.Scientific reports · 2026Article
- Applications of Metabolomics to the Clinical Management of Breast Cancer: New Perspectives for Diagnosis, Treatment and Prognosis.International journal of molecular sciences · 2026Review
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.Oncology research · 2026Review
- Impact of androgen receptor on triple negative breast cancer: a systematic review and meta-analytic study.BMJ public health · 2026Article
- Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.Current topics in medicinal chemistry · 2026Review
- Effects of SOX10 on the proliferative, invasive, migratory, and epithelial-mesenchymal transition abilities of triple-negative breast cancer cells.Frontiers in oncology · 2026Article
- The role of 3D culture models and advanced chromatography in exosome research for triple-negative breast cancer.Journal of the Egyptian National Cancer Institute · 2025Review
- Antibody-drug conjugates in triple-negative breast cancer (2010-2024): a bibliometric analysis of global trends and clinical translation.Discover oncology · 2025Article
- Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.Biomedicines · 2025Review
- Indian medicinal phytocompounds for targeting apoptosis and high-penetrance genes in triple-negative breast cancer: an in-silico exploration.BMC molecular and cell biology · 2025Article
- Correction: The molecular subtyping and precision medicine in triple-negative breast cancer--- based on Fudan TNBC classification.Cancer cell international · 2025Article
- A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline.Discover oncology · 2025Article
- Androgen receptor expression distribution characteristics in young female breast cancer patients in China: a study of clinicopathological features.Translational cancer research · 2025Article
- Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Review
- Application of TRPS1 in ER-negative or low expression distant metastatic breast carcinoma.Pathology oncology research : POR · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.